Faes Farma increases revenue by 12.3% to €307.4 million

July 24th, 2025

The pharmaceutical business grew by +9% to €269 million, with international markets (+14%) and licenses (+13%) continuing to be the main drivers of growth.

The three strategic molecules (Bilastine, Calcifediol and Mesalazine) totaled €127.7 million (+16%), representing 41.5% of the Group’s total revenues

Adjusted EBITDA stands at €80.5 million (+2.5%), in line with expectations

Financing for the Laboratorio Edol transaction has been completed and the debt for the acquisition of SIFI are currently being negotiated

Bilbao, July 24, 2025. – The Faes Farma Group today presented its results for the first half of 2025, with total revenues of €307.4 million (+12.3%), exceeding guidance thanks to growth in all business areas.

The Group’s two business areas performed well. On the one hand, the Pharma division, which accounts for 87.5% of total revenue in this period, grew by +9% to €269 million. FARM Faes, the animal nutrition and health division, grew by +48% to €38.3 million, with the ISF business (new plant in Huesca) as the main driver, with revenues exceeding expectations.

Revenue from the three strategic molecules—Bilastine with €82.7 million, Calcifediol with €33 million, and Mesalazine with €11.9 million—grew by a total of +16%, demonstrating their robust performance and representing 41.5% of the Group’s total revenue in this period.

Adjusted EBITDA for the first half of the year, i.e., excluding Edol (incorporated in June), extraordinary and one-off costs at Derio, and expenses arising from the recent M&A transactions involving Laboratorio Edol and SIFI, amounted to €80.5 million (+2.5%), in line with expectations. Reported EBITDA amounted to €73.3 million (-6.6%), within the most positive range of the guidance announced for the year, which ranges from -6% to -9%. Likewise, net profit for the first quarter reached €52.2 million, representing a decrease of 10.5% compared to the same period last year, impacted by both the extraordinary costs of Derio and those associated with M&A operations.

Growth in all divisions of the pharmaceutical business

In the Iberian pharmaceutical business, revenues reached €115.8 million (+ 5%), driven mainly by the performance of prescription products (medical visits), as well as the incorporation of Laboratorio Edol in Portugal in June.

Revenues from international markets totaled €81.7 million in this period (+14%). The Latin American region continued to perform well, with €53.2 million (+17%), as did the rest of the international countries, with €28.4 million (+9%). In Latin America, Colombia (+32%), Ecuador (+33%) and Peru (+24%) continue to perform very well based on the strategy to maximize bilastine and hydroferol products. In the rest of the countries, exports to distributors in Asia and the MENA region stand out as the largest contributors to sales, associated with more significant incremental margins. Faes Gulf grew by 6%, which will increase gradually during the year.

Licensing income totaled €72.8 million (+13%). Bilastine continued its positive performance from the first months of the year, particularly in existing markets (mainly in Eastern Europe and Southeast Asia), while new markets (Australia and China) began to contribute substantially. This completely offset the effect of the loss of exclusivity in Japan and Canada. Other licensing revenues amounted to €16.8 million (+37%), with a significant increase in Mesalazine thanks to strong local sales growth in Poland (where it achieved a leading position) and in the Nordic countries. New launches of calcifediol in key markets such as France, Poland, and the Baltic countries continue to gain market share, making it one of the main growth drivers in the business area.

Boosting growth with two acquisitions

As announced by the company in the presentation of its 2025-2030 Strategic Plan, this year will be the starting point for achieving its targets of €1 billion in revenue (CAGR of 11%-12%) and €240 million in EBITDA (CAGR of 10%-11%). This roadmap is aimed at strengthening organic growth and reinforcing the portfolio, promoting licensing agreements, investing in R&D&I for sustainable growth in the medium and long term, and complementing these levers through M&A.

Regarding this last pillar of inorganic growth, Faes Farma has already made significant progress with the recent acquisitions of Laboratorio Edol and SIFI, Portuguese and Italian companies, respectively, specializing in ophthalmology. In this regard, Faes Farma’s Extraordinary Shareholders’ Meeting approved the acquisition of 100% of SIFI on July 16, 2025.

These operations represent a transformational step in the future of Faes Farma, positioning it in the ophthalmology area with one of the most outstanding offerings on the market, generating significant synergies, strengthening its international position in new markets, and contributing very positively to the Group’s financial results.

For 2025, the company maintains its organic growth forecasts for the business and expects to close the year with revenue growth of between 8% and 10%. This strong performance will lead to an increase in adjusted EBITDA of between 3% and 5% and a decrease in reported EBITDA, with the exceptional effect of Derio, of between 6% and 9%.

R&D approvals

During the first half of the year, Faes Farma obtained approval for pediatric bilastine for children under 6 years of age in Europe. Likewise, in August, the long-awaited evaluation of the mesalazine 1.5 mg tablet dossier by the European regulatory authorities will begin. In addition, the clinical bioequivalence phase of three studies was completed in April.

The Faes Farma Group will hold a webcast scheduled for today, July 24, at 10:00 a.m. CET, to explain the main details of the results for the first half of 2025. The call will be open to the public and can be accessed via this link:

https://streamstudio.world-television.com/1506-2832-42063/es